PerkinElmer, Inc.

PerkinElmer, Inc.

PKI

$115.24

Updated: 23/09/2026, 10:14:56

Market Cap
$14.46B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US

No historical data available

Company Profile

PerkinElmer, Inc. operates as a global enterprise delivering innovative products, specialized services, and comprehensive solutions across the diagnostics, life sciences, and applied technology sectors. The company's operations are divided into two main segments: Discovery & Analytical Solutions, and Diagnostics. The Discovery & Analytical Solutions division furnishes scientists with an extensive suite of offerings, including chemical reagents, informatics platforms, and cutting-edge detection and imaging technologies. These resources are designed to accelerate research breakthroughs in the life sciences, and the segment also provides contract research and laboratory services. Additionally, it supplies analytical technologies, integrated solutions, and expert services to clients in the environmental, food, and industrial markets, aiding in the assessment and characterization of air, water, and soil quality. This segment further supports agricultural producers and food manufacturers, and delivers analytical instrumentation to a broad spectrum of industrial clients, encompassing chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment specializes in providing essential instruments, reagents, assay platforms, and software products for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its product range facilitates the testing and detection of various genetic abnormalities and conditions, such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and diverse metabolic disorders. Moreover, this segment develops enabling technologies that support advanced genomic workflows, leveraging methods like G-protein coupled receptor (GPCR) analysis and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery research. PerkinElmer's client base is diverse, including pharmaceutical and biotechnology companies, research laboratories, academic and scientific institutions, public health organizations, private healthcare providers, medical professionals, and governmental agencies. Founded in 1937, PerkinElmer, Inc. is headquartered in Waltham, Massachusetts.

USD
NYSE
CEO: Prahlad R. Singh
Employees: 16,700
https://www.perkinelmer.com
Asset Summaries
Latest generated summaries for PKI

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for PKI.
Share price
$115.24
Market cap
$14.46B
Exchange
NYSE
Currency
USD
CEO
Prahlad R. Singh
Employees
16,700
IPO date
06/04/1983
Beta
1.101337
Last dividend
$0.00
Day range
$114.67 – $117.21
52-week range
$113.17 – $170.00
1-day performance
-0.91%
1-year performance
1.83%
Current drawdown (1Y)
-32.21%
CIK
0000031791
CUSIP
714046109
ISIN
US7140461093
Created
07/12/2025, 05:46:20
Last update
23/09/2026, 10:14:56

Track PerkinElmer, Inc. with an AI analyst

See which prediction-market events move PKI, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to PKI from your Railway `news_articles` table.